Cargando…

Leveraging immune memory against measles virus as an antitumor strategy in a preclinical model of aggressive squamous cell carcinoma

Viral antigens are among the strongest elicitors of immune responses. A significant proportion of the human population already carries pre-existing immunity against several childhood viruses, which could potentially be leveraged to fight cancer. We sought to provide proof of concept in mouse models...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leb-Reichl, Victoria M, Kienzl, Melanie, Kaufmann, Anna, Stoecklinger, Angelika, Tockner, Birgit, Kitzmueller, Sophie, Zaborsky, Nadja, Steiner, Markus, Brachtl, Gabriele, Trattner, Lisa, Kreideweiss, Patrick, Reinsch, Christian, Panzner, Steffen, Greil, Richard, Strunk, Dirk, Bauer, Johann W, Gratz, Iris K, Guttmann-Gruber, Christina, Piñón Hofbauer, Josefina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Oncolytic and Local Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532558/ https://www.ncbi.nlm.nih.gov/pubmed/34675067 http://dx.doi.org/10.1136/jitc-2020-002170

Ejemplares similares

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
por: Cheng, Yinwen, et al.
Publicado: (2020)

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors
por: Siu, Lillian, et al.
Publicado: (2020)

Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination
por: Huang, Chung-Hsiung, et al.
Publicado: (2020)

Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication
por: Flores, Erica B, et al.
Publicado: (2020)

Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
por: Groeneveldt, Christianne, et al.
Publicado: (2020)

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning
por: Pol, Jonathan G, et al.
Publicado: (2020)

A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity
por: Huang, Feng-Ying, et al.
Publicado: (2020)

Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
por: Jung, Bo-Kyeong, et al.
Publicado: (2020)

Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
por: Crespo-Rodriguez, Eva, et al.
Publicado: (2020)

Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies
por: Tselikas, Lambros, et al.
Publicado: (2020)

Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B
por: Alvarez de Cienfuegos, Ana, et al.
Publicado: (2020)

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
por: Peluso, Marisa O, et al.
Publicado: (2020)

A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth
por: Gleisner, María Alejandra, et al.
Publicado: (2020)

Oncolytic vesicular stomatitis virus–based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8(+) T-cell functionality
por: Niavarani, Seyedeh-Raheleh, et al.
Publicado: (2020)

Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma
por: Wang-Bishop, Lihong, et al.
Publicado: (2020)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer
por: Lee, Yu Seong, et al.
Publicado: (2020)

IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy
por: Chen, Tianyue, et al.
Publicado: (2021)

Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy
por: Muñoz, Nina M., et al.
Publicado: (2021)

Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory
por: Hinterberger, Maria, et al.
Publicado: (2021)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
por: Ressler, Julia Maria, et al.
Publicado: (2021)

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche
por: Müller, Louise M E, et al.
Publicado: (2021)

Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial
por: Zhang, Bo, et al.
Publicado: (2021)

Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma
por: Beasley, Georgia M, et al.
Publicado: (2021)

Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity
por: Yu, Xiaofei, et al.
Publicado: (2021)

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
por: Allouchery, Marion, et al.
Publicado: (2020)

Neospora caninum: a new class of biopharmaceuticals in the therapeutic arsenal against cancer
por: Lantier, Louis, et al.
Publicado: (2020)

Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis
por: Gebremeskel, Simon, et al.
Publicado: (2021)

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma
por: Malvehy, Josep, et al.
Publicado: (2021)

New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models
por: Lopes, Alessandra, et al.
Publicado: (2021)

Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy
por: Khalique, Hena, et al.
Publicado: (2021)

T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A(+)CD141(+) cDC1 and CD14(+) antigen-presenting cell recruitment
por: Koster, Bas D, et al.
Publicado: (2021)

Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma
por: Morales-Molina, Alvaro, et al.
Publicado: (2021)

Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity
por: Anfray, Clément, et al.
Publicado: (2021)

Simple and effective bacterial-based intratumoral cancer immunotherapy
por: Carroll, Christina S E, et al.
Publicado: (2021)

Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments
por: Bhatta, Maulasri, et al.
Publicado: (2021)

Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy
por: Ghonime, Mohammed G, et al.
Publicado: (2021)

Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
por: Zhu, Yu-Chao, et al.
Publicado: (2021)

Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity
por: Taki, Shunichi, et al.
Publicado: (2021)

VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects
por: Bazan-Peregrino, Miriam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_girjed5es50il527kuh1c9d8jn